Skip to content

Summit Therapeutics SMMT Ratios & Valuation

TTM Q1 '26TTM Q4 '25TTM Q3 '25TTM Q2 '25TTM Q1 '25
Returns
Return on equity-271%-147pp-206.1%-111pp-292.5%-219pp-328.3%-226pp-123.9%+6.7pp
Return on assets-233.8%-148pp-181.9%-113pp-241.1%-187pp-224.1%-168pp-85.9%-32.1pp
Liquidity
Current ratio7.4×-3.2×9.9×-0.3×3.8×-4.5×5.1×+2.8×10.6×+3.7×
Quick ratio7.4×-3.2×9.9×-0.3×3.8×-4.5×5.1×+2.8×10.6×+3.7×
Cash ratio0.1×-0.1×0.2×-0.2×0.1×-0.1×0.1×0.0×0.2×0.0×
Leverage
Debt-to-equity0.0×0.0×0.0×0.0×-2.5×
Debt-to-assets0.0×0.0×0.0×0.0×-0.6×
Per Share
Book value per share$0.70+50.9%$0.88+62.9%$0.26-57.1%$0.35+26.8%$0.47+640%
Valuation
Market capitalization$14.7B+3.3%$13.02B-1.1%$15.35B-0.2%$15.54B+180%$14.23B+390%
Enterprise value$14.71B+3.4%$13.02B-1.0%$15.35B-0.1%$15.54B+181%$14.23B+372%
Price / book26.9×-14.4×19.8×-14.1×79.8×+44.7×59.9×+31.5×41.3×-24.4×
Free cash flow yield-2.6%-1.4pp-2.5%-1.4pp-1.8%-1.0pp-1.3%-1.2%
Earnings yield-8.2%-6.5pp-8.3%-6.6pp-6%-4.7pp-4.8%-1.9pp-1.7%+2.3pp

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where do Summit Therapeutics's ratios come from?
Every ratio is computed from Summit Therapeutics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.